Velcade Rebate Scheme In U.K. Sets Up Broader Cost-Effectiveness Review
Executive Summary
An innovative cost-sharing arrangement in which Johnson & Johnson will rebate the cost of the cancer drug Velcade (bortezomib) when patients have a minimal response will be implemented in the U.K. by early 2008
You may also be interested in...
Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time
Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.
UK-Style Insurance Risk-Sharing Could Affect Medicaid Rebates, Part B ASPs
U.S. biopharma manufacturers should be cautious about importing the British National Institute for Health and Clinical Excellence's approaches to reimbursement risk-sharing, as such schemes could have unanticipated consequences for obligations such as Medicaid rebates
UK-Style Insurance Risk-Sharing Could Affect Medicaid Rebates, Part B ASPs
U.S. biopharma manufacturers should be cautious about importing the British National Institute for Health and Clinical Excellence's approaches to reimbursement risk-sharing, as such schemes could have unanticipated consequences for obligations such as Medicaid rebates